<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568397</url>
  </required_header>
  <id_info>
    <org_study_id>15997</org_study_id>
    <secondary_id>I8D-MC-AZEE</secondary_id>
    <nct_id>NCT02568397</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants</brief_title>
  <official_title>Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about the effect of lanabecestat on how the body
      absorbs and processes dabigatran etexilate and how dabigatran etexilate affects lanabecestat
      when they are taken together. This study will last about 28 days and participants will be
      asked to take an lanabecestat tablet daily for 19 days and a dabigatran etexilate tablet on 3
      occasions. Screening is required within 30 days prior to the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2015</start_date>
  <completion_date type="Actual">January 31, 2016</completion_date>
  <primary_completion_date type="Actual">January 31, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) : Maximum Concentration (Cmax) of Dabigatran</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 36 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under The Dabigatran Pharmacokinetic (PK) Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity)</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 36 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Lanabecestat</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Lanabecestat Pharmacokinetic (PK) Concentration Versus Time Curve During One Dosing Interval (24 Hours) (AUCtau)</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Area Under the Effect Versus Time Curve (AUEC) of Thrombin Time</measure>
    <time_frame>Days 1, 16 and 20: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 36 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Ratio of Maximum Effect to Baseline Effect (ERmax) of Thrombin Time</measure>
    <time_frame>Days 1, 16 and 20: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 36 hours postdose</time_frame>
    <description>Ratio of maximum effect to baseline effect following administration of 150 mg dabigatran etexilate alone on Day 1, 50 mg LY3314814 and 150 mg dabigatran dosed concurrently on Day 16, and 50 mg LY3314814 and 150 mg dabigatran (dosed 4 hours later) on Day 20</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran Etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of dabigatran etexilate administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanabecestat and Dabigatran Etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of lanabecestat administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the lanabecestat dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanabecestat</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lanabecestat and Dabigatran Etexilate</arm_group_label>
    <other_name>LY3314814</other_name>
    <other_name>AZD3293</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Dabigatran Etexilate</arm_group_label>
    <arm_group_label>Lanabecestat and Dabigatran Etexilate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Overtly healthy males and females

        Exclusion Criteria:

          -  Eye abnormalities or disease

          -  History of vitiligo or any skin color disorder

          -  Have a history psychiatric or brain disease including seizures

          -  Have smoked within the last 3 months

          -  Are unwilling to avoid food and drinks containing grapefruit or Seville oranges for
             the duration of the study

          -  Have known allergies to dabigatran etexilate and related compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <results_first_submitted>December 13, 2018</results_first_submitted>
  <results_first_submitted_qc>April 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2019</results_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran Etexilate</title>
          <description>Single dose of dabigatran etexilate administered orally on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>LY3314814 + Dabigatran Etexilate</title>
          <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the LY3314814 dosing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">A single oral dose of 150 mg dabigatran etexilate was administered on Day 1 of Period 1.</participants>
                <participants group_id="P2" count="60">Daily doses of 50 mg LY3314814 were administered daily on Days 3 to 21 of Period 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Overall study population</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK) : Maximum Concentration (Cmax) of Dabigatran</title>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 36 hours postdose</time_frame>
        <population>All participants who received at least one dose of study drug and have evaluable pharmacokinetic (PK) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate</title>
            <description>Single dose of 150mg dabigatran etexilate administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>LY3314814 and Dabigatran Etexilate Day 16</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21. Concurrent single dose of dabigatran etexilate administered orally on day 16.</description>
          </group>
          <group group_id="O3">
            <title>LY3314814 and Dabigatran Etexilate Day 20</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21.Single dose of dabigatran etexilate administered orally 4 hours after LY3314814 administration on Day 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) : Maximum Concentration (Cmax) of Dabigatran</title>
          <population>All participants who received at least one dose of study drug and have evaluable pharmacokinetic (PK) data.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="69"/>
                    <measurement group_id="O2" value="148" spread="56"/>
                    <measurement group_id="O3" value="138" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under The Dabigatran Pharmacokinetic (PK) Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity)</title>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 36 hours postdose</time_frame>
        <population>All participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate</title>
            <description>Single dose of 150mg dabigatran etexilate administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>LY3314814 and Dabigatran Etexilate Day 16</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21. Concurrent single dose of dabigatran etexilate administered orally on day 16.</description>
          </group>
          <group group_id="O3">
            <title>LY3314814 and Dabigatran Etexilate Day 20</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21.Single dose of dabigatran etexilate administered orally 4 hours after LY3314814 administration on Day 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under The Dabigatran Pharmacokinetic (PK) Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity)</title>
          <population>All participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>nanogram*hour per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1090" spread="61"/>
                    <measurement group_id="O2" value="1240" spread="53"/>
                    <measurement group_id="O3" value="1110" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of Lanabecestat</title>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours postdose</time_frame>
        <population>All participants who received one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3314814 (AZD3293)</title>
            <description>50 mg LY3314814 administered orally alone on Day 15.</description>
          </group>
          <group group_id="O2">
            <title>LY3314814 and Dabigatran Etexilate Day 16</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21. Concurrent single dose of dabigatran etexilate administered orally on day 16.</description>
          </group>
          <group group_id="O3">
            <title>LY3314814 and Dabigatran Etexilate Day 20</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21.Single dose of dabigatran etexilate administered orally 4 hours after LY3314814 administration on Day 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of Lanabecestat</title>
          <population>All participants who received one dose of study drug and had evaluable PK data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342" spread="23"/>
                    <measurement group_id="O2" value="315" spread="21"/>
                    <measurement group_id="O3" value="331" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Lanabecestat Pharmacokinetic (PK) Concentration Versus Time Curve During One Dosing Interval (24 Hours) (AUCtau)</title>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
        <population>All participants who received one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3314814 (AZD3293)</title>
            <description>50 mg LY3314814 administered orally alone on Day 15</description>
          </group>
          <group group_id="O2">
            <title>LY3314814 and Dabigatran Etexilate Day 16</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21. Concurrent single dose of dabigatran etexilate administered orally on Day 16.</description>
          </group>
          <group group_id="O3">
            <title>LY3314814 and Dabigatran Etexilate Day 20</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21. Concurrent single dose of dabigatran etexilate administered orally on day 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Lanabecestat Pharmacokinetic (PK) Concentration Versus Time Curve During One Dosing Interval (24 Hours) (AUCtau)</title>
          <population>All participants who received one dose of study drug and had evaluable PK data.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3360" spread="25"/>
                    <measurement group_id="O2" value="3300" spread="26"/>
                    <measurement group_id="O3" value="3490" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Area Under the Effect Versus Time Curve (AUEC) of Thrombin Time</title>
        <time_frame>Days 1, 16 and 20: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 36 hours postdose</time_frame>
        <population>All participants who received at least one dose of study drug and had evaluable Pharmacodynamic (PD) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Extexilate Day 1</title>
            <description>Single dose of 150 mg dabigatran etexilate administered orally on Day 1</description>
          </group>
          <group group_id="O2">
            <title>LY3314814 and Dabigatran Etexilate Day 16</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21. Concurrent single dose of dabigatran etexilate administered orally on Day 16.</description>
          </group>
          <group group_id="O3">
            <title>LY3314814 and Dabigatran Etexilate Day 20</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21.Single dose of dabigatran etexilate administered orally 4 hours after LY3314814 administration on Day 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Area Under the Effect Versus Time Curve (AUEC) of Thrombin Time</title>
          <population>All participants who received at least one dose of study drug and had evaluable Pharmacodynamic (PD) data.</population>
          <units>seconds*hour (s*h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2080" spread="517"/>
                    <measurement group_id="O2" value="2170" spread="611"/>
                    <measurement group_id="O3" value="2030" spread="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Ratio of Maximum Effect to Baseline Effect (ERmax) of Thrombin Time</title>
        <description>Ratio of maximum effect to baseline effect following administration of 150 mg dabigatran etexilate alone on Day 1, 50 mg LY3314814 and 150 mg dabigatran dosed concurrently on Day 16, and 50 mg LY3314814 and 150 mg dabigatran (dosed 4 hours later) on Day 20</description>
        <time_frame>Days 1, 16 and 20: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 36 hours postdose</time_frame>
        <population>All participants who received at least one dose of study drug and had evaluable Pharmacodynamic (PD) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Extexilate Day 1</title>
            <description>Single dose of 150mg dabigatran etexilate administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>LY3314814 and Dabigatran Etexilate Day 16</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21. Concurrent single dose of dabigatran etexilate administered orally on Day 16.</description>
          </group>
          <group group_id="O3">
            <title>LY3314814 and Dabigatran Etexilate Day 20</title>
            <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21.Single dose of dabigatran etexilate administered orally 4 hours after LY3314814 administration on Day 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Ratio of Maximum Effect to Baseline Effect (ERmax) of Thrombin Time</title>
          <description>Ratio of maximum effect to baseline effect following administration of 150 mg dabigatran etexilate alone on Day 1, 50 mg LY3314814 and 150 mg dabigatran dosed concurrently on Day 16, and 50 mg LY3314814 and 150 mg dabigatran (dosed 4 hours later) on Day 20</description>
          <population>All participants who received at least one dose of study drug and had evaluable Pharmacodynamic (PD) data.</population>
          <units>ratio of maximum effect</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" lower_limit="3.49" upper_limit="7.84"/>
                    <measurement group_id="O2" value="7.09" lower_limit="1.06" upper_limit="7.84"/>
                    <measurement group_id="O3" value="7.00" lower_limit="1.10" upper_limit="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran Etexilate</title>
          <description>Single dose of 150mg dabigatran etexilate administered orally.</description>
        </group>
        <group group_id="E2">
          <title>LY3314814 (AZD3293)</title>
          <description>50 mg LY3314814 administered orally alone on Day 15</description>
        </group>
        <group group_id="E3">
          <title>LY3314814 and Dabigatran Etexilate Day 16</title>
          <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21. Concurrent single dose of dabigatran etexilate administered orally on Day 16.</description>
        </group>
        <group group_id="E4">
          <title>LY3314814 and Dabigatran Etexilate Day 20</title>
          <description>Single dose of LY3314814 administered orally once daily on Days 3 to 21. Concurrent single dose of dabigatran etexilate administered orally on day 20.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5079</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

